Operaciones FibroGen, Inc - FGEN CFD
Agregar a Favoritos- Resumen
- Datos históricos
- Eventos
- Cuenta de resultados
- Balance de situación
- Flujo de caja
- Propiedad
Condiciones de trading
| Diferencial | 0.24 | ||||||||
|
Tarifa nocturna posición alcista
Long position overnight fee
Ir a la plataforma | -0.025457% | ||||||||
|
Tarifa nocturna posición bajista
Short position overnight fee
Ir a la plataforma | 0.003235% | ||||||||
| Horario tarifa nocturna | 21:00 (UTC) | ||||||||
| Cantidad comercializada mínima | 1 | ||||||||
| Divisa | USD | ||||||||
| Margen | 20% | ||||||||
| Mercado de valores | United States of America | ||||||||
| Comisión por operación | 0% |
*Information provided by Capital.com
FibroGen Inc ESG Risk Ratings
High Medium Low Negligible
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Estadísticas clave
| Cierre previo* | 17.22 |
| Abrir* | 16.97 |
| Cambio de 1 año* | 72.46% |
| Rango del día* | 16.84 - 17.56 |
| Rango de 52 semanas | 8.67-25.69 |
| Volumen medio (10 días) | 801.43K |
| Volumen medio (3 meses) | 18.50M |
| Capitalización de mercado | 1.67B |
| Ratio P/E | -100.00K |
| Acciones en circulación | 97.58M |
| Ingresos | 116.07M |
| EPS | -3.27 |
| Dividendo (Rendimiento %) | N/A |
| Beta | 0.78 |
| Próxima fecha de resultados | Aug 7, 2023 |
"Todos los datos son proporcionados por Refinitiv, excepto los datos marcados con un asterisco, que son *datos proporcionados por Capital.com"
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Cierre | Change | Change (%) | Apertura | High | Low |
|---|---|---|---|---|---|---|
| May 31, 2023 | 17.16 | 0.15 | 0.88% | 17.01 | 17.61 | 16.72 |
| May 30, 2023 | 17.04 | 0.47 | 2.84% | 16.57 | 17.33 | 16.46 |
| May 26, 2023 | 16.65 | 0.03 | 0.18% | 16.62 | 16.80 | 16.33 |
| May 25, 2023 | 16.82 | 0.16 | 0.96% | 16.66 | 16.91 | 16.44 |
| May 24, 2023 | 16.90 | -0.05 | -0.29% | 16.95 | 17.33 | 16.51 |
| May 23, 2023 | 17.27 | 0.06 | 0.35% | 17.21 | 18.03 | 16.99 |
| May 22, 2023 | 17.16 | -0.14 | -0.81% | 17.30 | 18.02 | 16.96 |
| May 19, 2023 | 17.49 | -0.07 | -0.40% | 17.56 | 18.07 | 17.20 |
| May 18, 2023 | 17.53 | 0.01 | 0.06% | 17.52 | 17.89 | 17.29 |
| May 17, 2023 | 17.77 | 0.80 | 4.71% | 16.97 | 17.86 | 16.92 |
| May 16, 2023 | 17.40 | 0.25 | 1.46% | 17.15 | 17.51 | 17.08 |
| May 15, 2023 | 17.58 | 0.46 | 2.69% | 17.12 | 17.91 | 17.03 |
| May 12, 2023 | 17.31 | -0.11 | -0.63% | 17.42 | 17.66 | 17.09 |
| May 11, 2023 | 17.48 | -0.12 | -0.68% | 17.60 | 18.00 | 17.38 |
| May 10, 2023 | 17.65 | 0.25 | 1.44% | 17.40 | 17.84 | 17.17 |
| May 9, 2023 | 17.30 | 1.25 | 7.79% | 16.05 | 17.89 | 15.97 |
| May 8, 2023 | 17.61 | 0.58 | 3.41% | 17.03 | 17.73 | 16.55 |
| May 5, 2023 | 17.29 | 1.14 | 7.06% | 16.15 | 17.55 | 15.83 |
| May 4, 2023 | 16.68 | 0.36 | 2.21% | 16.32 | 16.85 | 15.93 |
| May 3, 2023 | 16.52 | 0.48 | 2.99% | 16.04 | 17.04 | 15.95 |
FibroGen, Inc Events
| Hora (UTC) (UTC) | País | Evento |
|---|---|---|
| Wednesday, June 7, 2023 | ||
| Hora (UTC) (UTC) 15:00 | País US
| Evento FibroGen Inc Annual Shareholders Meeting FibroGen Inc Annual Shareholders MeetingForecast -Previous - |
| Friday, June 16, 2023 | ||
| Hora (UTC) (UTC) 15:00 | País US
| Evento FibroGen Inc Annual Shareholders Meeting FibroGen Inc Annual Shareholders MeetingForecast -Previous - |
| Monday, August 7, 2023 | ||
| Hora (UTC) (UTC) 10:59 | País US
| Evento Q2 2023 FibroGen Inc Earnings Release Q2 2023 FibroGen Inc Earnings ReleaseForecast -Previous - |
| Monday, November 6, 2023 | ||
| Hora (UTC) (UTC) 10:59 | País US
| Evento Q3 2023 FibroGen Inc Earnings Release Q3 2023 FibroGen Inc Earnings ReleaseForecast -Previous - |
- Anual
- Trimestral
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Ingresos totales | 140.734 | 235.309 | 176.319 | 256.577 | 212.958 |
| Ingresos | 140.734 | 235.309 | 176.319 | 256.577 | 212.958 |
| Gastos totales de explotación | 441.759 | 523.839 | 368.199 | 345.891 | 299.651 |
| Gastos de venta/general/administración Gastos, total | 127.474 | 120.557 | 97.238 | 126.557 | 63.812 |
| Investigación y desarrollo | 296.791 | 387.043 | 252.924 | 209.265 | 235.839 |
| Ingresos de explotación | -301.025 | -288.53 | -191.88 | -89.314 | -86.693 |
| Ingresos por intereses (gastos), netos No operativos | 6.156 | -2.153 | 3.151 | 12.672 | 0.577 |
| Ingresos netos antes de impuestos | -294.869 | -290.683 | -188.729 | -76.642 | -86.116 |
| Ingresos netos después de impuestos | -295.227 | -291.03 | -189.089 | -76.97 | -86.42 |
| Beneficio neto antes de partidas extra. Elementos | -293.654 | -290.023 | -189.291 | -76.97 | -86.42 |
| Ingresos netos | -293.654 | -290.023 | -189.291 | -76.97 | -86.42 |
| Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | -293.654 | -290.023 | -189.291 | -76.97 | -86.42 |
| Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | -293.654 | -290.023 | -189.291 | -76.97 | -86.42 |
| Beneficio neto diluido | -293.654 | -290.023 | -189.291 | -76.97 | -86.42 |
| Promedio ponderado de acciones diluidas | 93.582 | 92.349 | 89.854 | 86.633 | 84.062 |
| BPA diluido sin partidas extraordinarias | -3.13793 | -3.14051 | -2.10665 | -0.88846 | -1.02805 |
| BPA normalizado diluido | -3.13793 | -3.14051 | -2.10665 | -0.88846 | -1.02805 |
| Total de partidas extraordinarias | |||||
| Coste de los ingresos, total | 20.28 | 12.871 | 8.869 | 1.147 | |
| Beneficio bruto | 120.454 | 222.438 | 167.45 | 255.43 | |
| Depreciation / Amortization | 0.587 | 4.639 | 10.369 | 10.307 | |
| Other Operating Expenses, Total | -3.373 | -1.271 | -1.201 | -1.385 | |
| Equity In Affiliates | 1.573 | 1.007 | -0.202 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Ingresos totales | 36.161 | 34.367 | 15.735 | 29.806 | 60.827 |
| Ingresos | 36.161 | 34.367 | 15.735 | 29.806 | 60.827 |
| Coste de los ingresos, total | 3.491 | 4.925 | 4.308 | 6.809 | 4.238 |
| Beneficio bruto | 32.67 | 29.442 | 11.427 | 22.997 | 56.589 |
| Gastos totales de explotación | 112.252 | 100.519 | 109.392 | 108.03 | 123.82 |
| Gastos de venta/general/administración Gastos, total | 34.275 | 33.966 | 29.902 | 30.258 | 30.564 |
| Investigación y desarrollo | 74.486 | 61.628 | 75.182 | 70.963 | 89.018 |
| Other Operating Expenses, Total | |||||
| Ingresos de explotación | -76.091 | -66.152 | -93.657 | -78.224 | -62.993 |
| Ingresos por intereses (gastos), netos No operativos | -1.336 | -0.195 | 1.714 | 5.058 | -0.419 |
| Ingresos netos antes de impuestos | -77.427 | -66.347 | -91.943 | -73.166 | -63.412 |
| Ingresos netos después de impuestos | -77.501 | -66.455 | -92.057 | -73.189 | -63.525 |
| Equity In Affiliates | 0.796 | 0.28 | 0.407 | 0.565 | 0.32 |
| Beneficio neto antes de partidas extra. Elementos | -76.705 | -66.175 | -91.65 | -72.624 | -63.205 |
| Ingresos netos | -76.705 | -66.175 | -91.65 | -72.624 | -63.205 |
| Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | -76.705 | -66.175 | -91.65 | -72.624 | -63.205 |
| Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | -76.705 | -66.175 | -91.65 | -72.624 | -63.205 |
| Beneficio neto diluido | -76.705 | -66.175 | -91.65 | -72.624 | -63.205 |
| Promedio ponderado de acciones diluidas | 94.691 | 94.035 | 93.767 | 93.475 | 93.043 |
| BPA diluido sin partidas extraordinarias | -0.81006 | -0.70373 | -0.97742 | -0.77694 | -0.67931 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| BPA normalizado diluido | -0.81006 | -0.70373 | -0.97742 | -0.77694 | -0.67931 |
- Anual
- Trimestral
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Activo Corriente | 492.826 | 474.059 | 755.11 | 702.49 | 690.015 |
| Efectivo e inversiones a corto plazo | 422.008 | 405.19 | 686.537 | 533.757 | 621.402 |
| Cash | 135.819 | 111.422 | 88.046 | 40.715 | 38.783 |
| Efectivo y Equivalentes | 19.881 | 59.801 | 590.347 | 85.551 | 50.475 |
| Inversiones a corto plazo | 266.308 | 233.967 | 8.144 | 407.491 | 532.144 |
| Total deudores, neto | 16.299 | 25.401 | 41.883 | 153.665 | 63.684 |
| Accounts Receivable - Trade, Net | 28.387 | 36.331 | 46.01 | 158.51 | 16.474 |
| Prepaid Expenses | 9.73 | 7.383 | 8.353 | 6.464 | 4.929 |
| Total Assets | 610.087 | 773.821 | 826.84 | 857.397 | 880.598 |
| Property/Plant/Equipment, Total - Net | 100.933 | 120.15 | 65.296 | 84.276 | 127.198 |
| Property/Plant/Equipment, Total - Gross | 253.644 | 252.362 | 199.305 | 195.752 | 192.397 |
| Accumulated Depreciation, Total | -152.711 | -132.212 | -134.009 | -111.476 | -65.199 |
| Long Term Investments | 9.409 | 171.621 | 2.972 | 61.118 | 55.82 |
| Other Long Term Assets, Total | 6.919 | 7.991 | 3.462 | 9.513 | 7.565 |
| Total Current Liabilities | 273.562 | 225.497 | 163.187 | 102.745 | 89.033 |
| Accounts Payable | 30.758 | 26.097 | 24.789 | 6.088 | 9.139 |
| Accrued Expenses | 229.639 | 180.356 | 104.384 | 83.816 | 66.123 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 13.129 | 19.033 | 21.684 | 0.49 | 13.771 |
| Total Liabilities | 631.534 | 564.675 | 404.662 | 341.262 | 371.399 |
| Total Long Term Debt | 17.054 | 17.616 | 44.088 | 55.531 | 113.955 |
| Long Term Debt | 16.917 | 17.613 | 18.697 | 16.78 | 16.798 |
| Capital Lease Obligations | 0.137 | 0.003 | 25.391 | 38.751 | 97.157 |
| Minority Interest | 19.967 | 19.967 | 19.271 | 19.271 | 19.271 |
| Other Liabilities, Total | 320.951 | 292.403 | 169.441 | 163.715 | 149.14 |
| Total Equity | -21.447 | 209.146 | 422.178 | 516.135 | 509.199 |
| Redeemable Preferred Stock | 0 | 0 | 0 | 0 | 0 |
| Common Stock | 0.942 | 0.929 | 0.914 | 0.877 | 0.854 |
| Additional Paid-In Capital | 1541.02 | 1476.41 | 1399.77 | 1300.72 | 1226.45 |
| Retained Earnings (Accumulated Deficit) | -1557.69 | -1264.03 | -974.011 | -784.72 | -715.827 |
| Other Equity, Total | -5.72 | -4.163 | -4.499 | -0.747 | -2.281 |
| Total Liabilities & Shareholders’ Equity | 610.087 | 773.821 | 826.84 | 857.397 | 880.598 |
| Total Common Shares Outstanding | 94.1661 | 92.881 | 91.441 | 87.657 | 85.432 |
| Total Inventory | 40.436 | 31.015 | 16.53 | 6.887 | |
| Other Current Assets, Total | 4.353 | 5.07 | 1.807 | 1.717 | |
| Current Port. of LT Debt/Capital Leases | 0.036 | 0.011 | 12.33 | 12.351 | |
| Deferred Income Tax | 9.192 | 8.675 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Total Activo Corriente | 430.549 | 492.826 | 474.224 | 520.643 | 524.415 |
| Efectivo e inversiones a corto plazo | 355.949 | 422.008 | 408.52 | 438.133 | 428.075 |
| Cash | 145.81 | 135.819 | 104.509 | 128.152 | 165.436 |
| Efectivo y Equivalentes | 42.74 | 19.881 | 51.451 | 39.606 | 20.46 |
| Inversiones a corto plazo | 167.399 | 266.308 | 252.56 | 270.375 | 242.179 |
| Total deudores, neto | 17.654 | 16.299 | 15.328 | 33.573 | 43.883 |
| Accounts Receivable - Trade, Net | 29.217 | 28.387 | 29.665 | 60.352 | 82.638 |
| Total Inventory | 42.456 | 40.436 | 39.95 | 40.899 | 43.067 |
| Prepaid Expenses | 14.49 | 9.73 | 10.426 | 8.038 | 9.39 |
| Other Current Assets, Total | 4.353 | ||||
| Total Assets | 538.544 | 610.087 | 608.837 | 686.789 | 745.934 |
| Property/Plant/Equipment, Total - Net | 95.367 | 100.933 | 105.19 | 109.159 | 114.871 |
| Property/Plant/Equipment, Total - Gross | 253.644 | ||||
| Accumulated Depreciation, Total | -152.711 | ||||
| Long Term Investments | 5.884 | 9.409 | 22.411 | 50.414 | 97.643 |
| Other Long Term Assets, Total | 6.744 | 6.919 | 7.012 | 6.573 | 9.005 |
| Total Current Liabilities | 254.746 | 273.562 | 251.994 | 240.34 | 255.374 |
| Accounts Payable | 71.282 | 30.758 | 19.323 | 29.36 | 36.353 |
| Accrued Expenses | 166.969 | 229.639 | 224.577 | 202.681 | 211.518 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 0.036 | ||||
| Other Current Liabilities, Total | 16.495 | 13.129 | 8.094 | 8.299 | 7.503 |
| Total Liabilities | 587.396 | 631.534 | 582.531 | 583.009 | 587.886 |
| Total Long Term Debt | 17.276 | 17.054 | 15.422 | 16.439 | 17.374 |
| Long Term Debt | 17.276 | 16.917 | 15.422 | 16.439 | 17.374 |
| Capital Lease Obligations | 0.137 | ||||
| Deferred Income Tax | |||||
| Minority Interest | 19.967 | 19.967 | 19.967 | 19.967 | 19.967 |
| Other Liabilities, Total | 295.407 | 320.951 | 295.148 | 306.263 | 295.171 |
| Total Equity | -48.852 | -21.447 | 26.306 | 103.78 | 158.048 |
| Redeemable Preferred Stock | 0 | 0 | 0 | 0 | |
| Common Stock | 0.966 | 0.942 | 0.939 | 0.937 | 0.933 |
| Additional Paid-In Capital | 1589.15 | 1541.02 | 1524.23 | 1509.64 | 1490.86 |
| Retained Earnings (Accumulated Deficit) | -1634.39 | -1557.69 | -1491.51 | -1399.86 | -1327.24 |
| Other Equity, Total | -4.57 | -5.72 | -7.346 | -6.93 | -6.505 |
| Total Liabilities & Shareholders’ Equity | 538.544 | 610.087 | 608.837 | 686.789 | 745.934 |
| Total Common Shares Outstanding | 96.623 | 94.1661 | 93.936 | 93.733 | 93.289 |
- Anual
- Trimestral
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Ingresos netos/Línea de salida | -293.654 | -290.023 | -189.291 | -76.97 | -86.42 |
| Efectivo de actividades de explotación | -145.933 | -82.232 | 81.602 | -78.705 | -76.144 |
| Efectivo de actividades de explotación | 10.604 | 14.809 | 22.047 | 21.454 | 6.562 |
| Partidas no monetarias | 66.687 | 132.899 | 74.216 | 62.47 | 52.112 |
| Intereses pagados en efectivo | 0.104 | 0.094 | 0.135 | 0.174 | 0.218 |
| Cambios en el capital circulante | 70.43 | 60.083 | 174.63 | -85.659 | -48.398 |
| Efectivo de actividades de inversión | 89.116 | -426.972 | 452.487 | 120.018 | -522.123 |
| Gastos de capital | -38.741 | -30.186 | -3.994 | -5.762 | -8.02 |
| Otras partidas de flujo de caja de inversión, total | 127.857 | -396.786 | 456.481 | 125.78 | -514.103 |
| Efectivo procedente de actividades de financiación | 46.776 | -0.563 | 13.343 | -4.3 | 13.875 |
| Elementos de flujo de caja de financiación | -6.62 | -7.372 | -11.463 | -12.75 | -15.612 |
| Emisión (retiro) de acciones, neto | 53.934 | 12.701 | 37.829 | 20.778 | 29.847 |
| Emisión (amortización) de deuda, neta | -0.538 | -5.892 | -13.023 | -12.328 | -0.36 |
| Efectos del cambio de divisas | -5.482 | 2.597 | 4.695 | -0.005 | -0.008 |
| Variación neta de la tesorería | -15.523 | -507.17 | 552.127 | 37.008 | -584.4 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -76.705 | -293.654 | -227.479 | -135.829 | -63.205 |
| Cash From Operating Activities | -101.591 | -145.933 | -93.42 | -41.54 | -8.476 |
| Cash From Operating Activities | 2.965 | 10.604 | 7.914 | 5.235 | 2.584 |
| Non-Cash Items | 18.148 | 66.687 | 49.928 | 34.441 | 17.77 |
| Changes in Working Capital | -45.999 | 70.43 | 76.217 | 54.613 | 34.375 |
| Cash From Investing Activities | 103.482 | 89.116 | 88.023 | 43.24 | 25.935 |
| Capital Expenditures | -0.591 | -38.741 | -38.408 | -37.543 | -36.638 |
| Other Investing Cash Flow Items, Total | 104.073 | 127.857 | 126.431 | 80.783 | 62.573 |
| Cash From Financing Activities | 31.485 | 46.776 | -1.898 | -0.806 | -2.893 |
| Financing Cash Flow Items | 0 | -6.62 | -4.562 | -3.361 | -2.974 |
| Issuance (Retirement) of Stock, Net | 31.657 | 53.934 | 2.989 | 2.779 | 0.183 |
| Issuance (Retirement) of Debt, Net | -0.172 | -0.538 | -0.325 | -0.224 | -0.102 |
| Foreign Exchange Effects | -0.526 | -5.482 | -7.968 | -4.359 | 0.107 |
| Net Change in Cash | 32.85 | -15.523 | -15.263 | -3.465 | 14.673 |
| Nombre del Inversor | Tipo de inversor | Porcentaje pendiente | Acciones en propiedad | Cambio de acciones | Fechas de holding | Índice de rotación |
|---|---|---|---|---|---|---|
| PRIMECAP Management Company | Investment Advisor | 14.4767 | 14126697 | 231619 | 2023-03-31 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 9.0286 | 8810326 | -613439 | 2023-03-31 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 6.2737 | 6122003 | 89685 | 2023-03-31 | LOW |
| Astellas Pharma Inc | Corporation | 5.0915 | 4968367 | 0 | 2023-01-31 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 4.1772 | 4076167 | -188810 | 2023-03-31 | LOW |
| Point72 Asset Management, L.P. | Hedge Fund | 3.5113 | 3426427 | -1355218 | 2023-03-31 | LOW |
| First Trust Advisors L.P. | Investment Advisor | 2.7884 | 2720975 | -254678 | 2023-03-31 | LOW |
| Baker Bros. Advisors LP | Hedge Fund | 2.7027 | 2637384 | 1262173 | 2023-03-31 | LOW |
| Armistice Capital LLC | Hedge Fund | 2.3693 | 2312000 | -1552000 | 2023-03-31 | HIGH |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.7703 | 1727545 | 70450 | 2023-03-31 | LOW |
| Two Sigma Investments, LP | Hedge Fund | 1.7676 | 1724909 | 512435 | 2023-03-31 | HIGH |
| Schroder Investment Management North America Inc. | Investment Advisor | 1.5138 | 1477161 | -246616 | 2023-03-31 | LOW |
| Artisan Partners Limited Partnership | Investment Advisor | 1.3847 | 1351230 | 1351230 | 2023-03-31 | LOW |
| Assenagon Asset Management S.A. | Investment Advisor | 1.3779 | 1344583 | 1344583 | 2023-03-31 | HIGH |
| Jacobs Levy Equity Management, Inc. | Investment Advisor/Hedge Fund | 1.1877 | 1159027 | -348288 | 2023-03-31 | MED |
| Pictet Asset Management Ltd. | Investment Advisor/Hedge Fund | 1.1157 | 1088768 | 593915 | 2023-03-31 | LOW |
| Eventide Asset Management, LLC | Investment Advisor | 0.9838 | 960000 | 960000 | 2023-03-31 | MED |
| Nuveen LLC | Pension Fund | 0.9185 | 896293 | 328958 | 2023-03-31 | LOW |
| Adage Capital Management, L.P. | Hedge Fund | 0.8711 | 850000 | -1800000 | 2023-03-31 | LOW |
| Eagle Asset Management, Inc. | Investment Advisor/Hedge Fund | 0.8488 | 828307 | -74825 | 2023-03-31 | LOW |
¿Por qué operar con Capital.com? Nuestros números hablan por nosotros
Capital.com Group535K+
Traders
87K+
Clientes activos mensualmente
$113M+
Volumen mensual de inversión
$64M+
Retiros por mes
Calculadora de trading
Calcula tus P&L hipotéticas en el supuesto de haber abierto una operación con CFD en una fecha determinada (selecciona una fecha) y haberla cerrado en otra fecha (selecciona una fecha).
Comisión de la operación
0
- 1:1
Apalancamiento
1:1
- 20
- 100
- 500
- 1000
- 10000
Inversión
Tamaño de la operación (Apalancamiento x Inversión)
Apertura
Cierre
En corto En largo
FibroGen, Inc Company profile
Sobre FibroGen Inc
FIBROGEN, INC. es una compañía biofarmacéutica basada en la investigación que descubre y desarrolla medicamentos de primera clase terapéutica. La Compañía se dedica al desarrollo biológico y clínico de la fibrosis y factor inducible por la hipoxia (HIF) para avanzar el uso de medicinas innovadoras en el tratamiento la de anemia, enfermedades fibróticas y cáncer. Roxadustat, el medicamento más avanzado de la Compañía, es un inhibidor oral de molécula pequeña con actividad de prolil hidroxilasa de HIF en fase III de desarrollo clínico para el tratamiento de la anemia en la enfermedad renal crónica (ERC), y está entrando en la fase III de desarrollo de la anemia en síndromes mielodisplásicos (SMD) con riesgo menor. La Compañía ha desarrollado Pamrevlumab. Pamrevlumab es un anticuerpo terapéutico patentado para inhibir la actividad del factor de crecimiento de tejido conectivo (CTGF), un factor común en trastornos fibróticos crónicos y proliferativos caracterizados por cicatrización persistente y excesiva que puede conducir a la disfunción y fracaso de órganos.
El precio actual de la acción FibroGen, Inc en tiempo real es 17.25 USD. El gráfico de la acción permite a los inversores comprender mejor el rendimiento y el precio de la acción y tomar decisiones informadas al negociar acciones y CFD.
Descubra más acciones con gráficos, datos vitales y actualizaciones de precios en tiempo real: Hwa Hong, CureVac N.V., Atomera Incorporated, PT Kalbe Farma Tbk., Oceanus y UnitedHealth Group. Para obtener más información, consulte los perfiles de las empresas en Capital.com.
| Industry: | Biotechnology & Medical Research (NEC) |
409 Illinois Street
SAN FRANCISCO
CALIFORNIA 94158
US
Cuenta de resultados
- Annual
- Quarterly
A la gente también le interesa
¿Aún estás buscando un bróker de confianza?
Únete a más de 535.000 traders de todo el mundo que eligen operar con Capital.com